NASDAQ · Biotechnology

PureTech Health plc (PRTC) Stock

$16.63 +0.85% NASDAQ: PRTC Healthcare

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.

Valuation

MetricValue
Price$16.63
Market Cap$404.84M
P/E Ratio-0.58
P/B Ratio0.13
P/S Ratio87.09
EPS (TTM)$-46.00
52-Week High$19.92
52-Week Low$14.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-31.83%
ROA-20.48%
ROCE-20.13%
Gross Margin-471.15%
Operating Margin-1980.00%
Net Margin-2200.00%
Debt/Equity0.06
Current Ratio6.59

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$2.0M$3.0M$5.0M$5.0M
Operating Profit$-150.0M$-198.0M$-146.0M$-136.0M$-99.0M
Net Profit$-61.0M$-50.0M$-66.0M$54.0M$-110.0M
EPS$-2.10$-1.80$-2.40$2.00$-46.00
Op Margin-1506.0%-9464.5%-4390.4%-2818.9%-2114.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$946.0M$703.0M$694.0M$603.0M$535.0M
Total Liabilities$362.0M$155.0M$236.0M$195.0M$229.0M
Cash$466.0M$150.0M$191.0M$281.0M$254.0M
Borrowings$53.0M$47.0M$25.0M$22.0M$20.0M

Latest News

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Business Wire · Jul 13, 2026 Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial Clinical Trials Arena · Jul 3, 2026 A PureTech startup banks $180M for a new IPF drug BioPharma Dive · Jul 2, 2026 Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Business Wire · Jul 2, 2026 PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Business Wire · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-158.0M$-179.0M$-106.0M$-134.0M$-85.0M
Investing Cash Flow$192.0M$-109.0M$69.0M$241.0M$63.0M
Financing Cash Flow$21.0M$-31.0M$80.0M$-14.0M$-6.0M
Net Cash Flow$62.0M$-316.0M$41.0M$90.0M$-28.0M
Free Cash Flow$-164.0M$-181.0M$-106.0M$-134.0M$-85.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.79
FCF Yield-20.95%
Quick Ratio6.59
Interest Coverage-2.16
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLYM $14.00 +0.00% -11.77 $801.68M 0.00%
GNTAGenenta Science S.p.A. $1.50 -5.66% -3.98 $28.72M 0.00%
INBXInhibrx Biosciences Inc. $81.54 -0.01% -9.72 $1.20B 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
KROS $10.42 +2.06% 4.60 $333.42M 0.00%

About PureTech Health plc

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

PureTech Health plc is headquartered in US.

PureTech Health plc (PRTC) stock trades at $16.63 with a market capitalization of $404.84M. The stock is valued at a price-to-earnings (P/E) ratio of -0.58, price-to-book of 0.13, price-to-sales of 87.09. Over the past 52 weeks the stock has ranged between $14.50 and $19.92, and currently trades 16.5% below its 52-week high.

On profitability, PureTech Health plc generates a return on equity (ROE) of -31.83%, return on capital employed of -20.13%, an operating margin of -1980.00%, a net profit margin of -2200.00%.

Official website: puretechhealth.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides